Page last updated: 2024-11-11

bc 197

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6449837
MeSH IDM0167305

Synonyms (10)

Synonym
115295-08-4
boc-asp-tyr(so3h)-ahx-lys-trp-ahx-asp-phe-nh2
boc-asp-tyr(so3h)-nle-lys-trp-nle-asp-phe-nh2
bc-197
l-phenylalaninamide, n-((1,1-dimethylethoxy)carbonyl)-d-alpha-aspartyl-o-sulfo-l-tyrosyl-l-norleucyl-d-lysyl-l-tryptophyl-l-norleucyl-l-alpha-aspartyl-, cyclic (1-4)-peptide
boc-aspartyl-tyrosyl(so3h)-norelucyl-lysyl-tryptophyl-norleucyl-aspartyl-phenylalaninamide
l-phenylalaninamide, n- ((1,1-dimethylethoxy)carbonyl)-d-alpha-aspartyl-o-sulfo-l-tyrosyl-l-norleucyl-d-lysyl-l-tryptophyl-l-norleucyl-l-alpha-aspartyl-, cyclic (1-4)-peptide
bc 197
(3r)-4-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-6-amino-2-[[(2s,3e)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]hexa-3,5-dienyl]amino]hexanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-oxo-4-sulfooxybutanoyl]amino]-3-phenylpropan
(2s,5s,8r,11s,14s,17s,20s,24r)-11-((1h-indol-3-yl)methyl)-2-amino-8-(4-aminobutyl)-20-benzyl-5-((e)-buta-1,3-dien-1-yl)-24-((tert-butoxycarbonyl)amino)-14-butyl-1-(4-hydroxyphenyl)-3,9,12,15,18,21,23-heptaoxo-17-(2-oxo-2-(sulfooxy)ethyl)-4,7,10,13,16,19,2

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Lys-Trp-Nle-Asp-Phe-NH2) was ineffective to modify the self-stimulation behaviour when administered alone while a 150 pmol BC-197 dosage was able to antagonize the decreasing effect of 150 pmol CCK-8 on ICSS."( Similar potencies of CCK-8 and its analogue BOC(Nle28;Nle31)CCK27-33 on the self-stimulation behaviour both are antagonized by a newly synthesized cyclic CCK analogue.
De Witte, P; Heidbreder, C; Roques, BP,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (85.71)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.61 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]